MARLBOROUGH, Mass., June 24, 2014 /PRNewswire/ -- Lemelson Capital Management, a private investment management firm, today reaffirmed the analysis presented in its 25-page research report on Ligand Pharmaceuticals (NASDAQ: LGND), released originally on June 16, 2014, and the projected price target for its shares.

"Despite nearly 16% correction in LGND shares since the report was  published six trading days ago, we continue to affirm that the intrinsic value of its shares is immaterial," said Lemelson Capital Management Chief Investment Officer Emmanuel Lemelson.

Lemelson Capital's full research report on Ligand can be found here  

Disclosure:  Lemelson Capital is currently short shares of LGND for its clients.

About Lemelson Capital Management

Lemelson Capital Management, LLC is a private investment management firm focused on deep value and special situation investments.  The firm's flagship fund, The Amvona Fund, has been named repeatedly one of the world's top performing hedge funds.  For more information, see: http://www.lemelsoncapital.com

For further information, contact:

+ Emmanuel Lemelson 
Chief Investment Officer 
Lemelson Capital Management, LLC 

Telephone: 508-630-2281

SOURCE Lemelson Capital Management, LLC